[Letter to the Editor] Genetic Control
By Marcy Darnovsky,
The New Yorker
| 12. 14. 2015
Specter highlights exciting developments in the field of gene editing, but he is too quick to dismiss the shadow side. Writing that CRISPR “offers a new outlet for the inchoate fear of tinkering with the fundamentals of life” is an inadequate characterization of the risks involved. The piece describes a nightmare of Jennifer Doudna’s, in which she tutors Hitler about editing genes, but does not reference Eric Lander’s sober warning, in an article on heritable genome manipulation, in the New England Journal of Medicine. Specter does not mention that dozens of countries, including most with developed biotech sectors, have written prohibitions on heritable genetic manipulation into their laws, and into a binding international treaty. In distinguishing the public—and its advocates—from scientists, Specter might lead readers to erroneously believe that researchers are not deeply concerned. Nearly all scientists want a broad public debate about what kind of gene editing should be pursued. This is a potentially society-altering technology, and democratic engagement with its trajectory is crucial and pressing.
Marcy Darnovsky
Executive Director, Center for Genetics and Society
Berkeley, Calif.
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...